Scientific article
Open access

S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects

Published inScience advances, vol. 10, no. 1, eadj4686
Publication date2024-01-05

Type 1 diabetes mellitus (T1DM) is characterized by insulin deficiency leading to hyperglycemia and several metabolic defects. Insulin therapy remains the cornerstone of T1DM management, yet it increases the risk of life-threatening hypoglycemia and the development of major comorbidities. Here, we report an insulin signaling–independent pathway able to improve glycemic control in T1DM rodents. Co-treatment with recombinant S100 calcium-binding protein A9 (S100A9) enabled increased adherence to glycemic targets with half as much insulin and without causing hypoglycemia. Mechanistically, we demonstrate that the hyperglycemia-suppressing action of S100A9 is due to a Toll-like receptor 4–dependent increase in glucose uptake in specific skeletal muscles (i.e., soleus and diaphragm). In addition, we found that T1DM mice have abnormal systemic inflammation, which is resolved by S100A9 therapy alone (or in combination with low insulin), hence uncovering a potent anti-inflammatory action of S100A9 in T1DM. In summary, our findings reveal the S100A9-TLR4 skeletal muscle axis as a promising therapeutic target for improving T1DM treatment.

Citation (ISO format)
URSINO, Gloria et al. S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects. In: Science advances, 2024, vol. 10, n° 1, p. eadj4686. doi: 10.1126/sciadv.adj4686
Main files (1)
Article (Published version)
Secondary files (1)
ISSN of the journal2375-2548

Technical informations

Creation01/12/2024 2:04:39 PM
First validation01/17/2024 1:20:22 PM
Update time01/17/2024 1:20:22 PM
Status update01/17/2024 1:20:22 PM
Last indexation05/06/2024 5:45:51 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack